Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Treace Medical Concepts (TMCI)
NASDAQ:TMCI
RESEARCH TOOLSreports
Holding TMCI?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.1Same Quarter Last Year
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Aug 05, 2021
|% Change Since: 64.24%
|Next Earnings Date:May 25, 2021
Earnings Call Sentiment|Positive
The earnings call presented a mix of positive developments and challenges. Highlights included strong revenue growth, successful product launches, and improved reimbursement rates, suggesting strategic progress and financial improvements. However, increased operating expenses, ongoing net losses, and potential market challenges were notable concerns. Overall, the company's growth initiatives and financial improvements slightly outweigh the challenges.Company Guidance
During the Treace Medical Concepts Q3 2024 earnings call, the company revised its full-year revenue guidance to $204 million to $211 million, reflecting a growth of 9% to 13% over 2023. The third quarter revenue was $45.1 million, marking an 11% increase compared to the same period in 2023. The gross margin remained stable at 80.1%. The company reported a net loss of $15.4 million, or $0.25 per share, an improvement from a $17.5 million loss in Q3 2023. The adjusted EBITDA loss was reduced by 45% year-over-year to $5.1 million. Treace highlighted the limited market release of its Nanoplasty 3D MIS system and anticipated continued growth through its innovative product pipeline. The Centers for Medicare & Medicaid Services (CMS) also reassigned a key CPT code, significantly increasing the reimbursement rates for 2025, which could potentially enhance patient access and procedure volumes.Revenue Growth
Third quarter revenue was $45.1 million, representing 11% growth over the third quarter of 2023.
New Product Launch
Announced a limited market release of the Nanoplasty 3D MIS system, entering the large metatarsal osteotomy market.
Revised Revenue Guidance
Revised full year 2024 revenue guidance to $204 million to $211 million, reflecting an increase of 9% to 13% over 2023 revenue.
Improvement in Adjusted EBITDA
Adjusted EBITDA loss in the third quarter was $5.1 million, an improvement of 45% compared to the loss of $9.2 million in Q3 2023.
Positive Reimbursement Updates
CMS reassignment of CPT code 28297 with a significant increase in hospital outpatient and ASC payment rates for 2025.
---
TMCI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TMCI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $5.76 | $7.78 | +35.07% |
| Aug 06, 2024 | $6.66 | $6.50 | -2.40% |
| May 07, 2024 | $11.12 | $4.17 | -62.50% |
| Feb 27, 2024 | $14.38 | $13.52 | -5.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Treace Medical Concepts (TMCI) report earnings?
Treace Medical Concepts (TMCI) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Treace Medical Concepts (TMCI) earnings time?
Treace Medical Concepts (TMCI) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TMCI EPS forecast?
TMCI EPS forecast for the fiscal quarter 2024 (Q4) is -0.04.
---